Delving into the Latest Updates on BAH-1 (Genentech) with Synapse

Overview

Basic Info

Drug Type

Monoclonal antibody

Synonyms

thrombopoietin stimulating Mab (Genentech)

Target-

Action-

Mechanism-

Therapeutic Areas

Hemic and Lymphatic Diseases

Active Indication-

Inactive Indication

Thrombocytopenia

Originator Organization

Genentech, Inc.

Active Organization-

Inactive Organization

Genentech, Inc.

License Organization-

Drug Highest PhasePendingDiscovery

First Approval Date-

Regulation-

ABSTRACTThis study aimed to investigate the protective mechanisms of dexmedetomidine (Dex) and thrombopoietin (TPO) against hypoxia/reoxygenation (H/R)‐induced myocardial injury. Human cardiomyocyte AC16 cells were subjected to hypoxic conditions and treated with Dex and TPO. Cellular responses, including proliferation, apoptosis, and autophagy, were assessed. RNA sequencing and bioinformatic analyses were conducted to identify differentially expressed genes, followed by functional pathway enrichment analysis. The results demonstrated that Dex and TPO significantly promoted cell proliferation, reduced apoptosis and autophagy, and inhibited caspase‐3 activity and light chain 3B (LC3B) expression. Pathway enrichment analysis revealed the involvement of mitogen‐activated protein kinase (MAPK), transforming growth factor beta (TGF‐β), and tumor necrosis factor (TNF) signaling pathways. Although both treatments demonstrated overlapping effects, they also exhibited distinct gene regulation mechanisms. These findings suggested that Dex and TPO could mitigate H/R‐induced myocardial injury through complex gene regulatory mechanisms, highlighting their potential as therapeutic strategies for myocardial ischemia–reperfusion injury (MIRI).

01 Mar 2025·Journal of Veterinary Internal Medicine

Response to Second Letter on Response Letter Regarding “Plasma Concentration of Thrombopoietin in Dogs With Immune Thrombocytopenia”

Letter

Author: Wagner, Bettina ; Babasyan, Susanna ; Goggs, Robert ; Brooks, Marjory B. ; Catalfamo, Jim ; Brooks, James C. ; LeVine, Dana H. ; Zhu, Yao

01 Mar 2025·Journal of Veterinary Internal Medicine

Response to Response to Letter Regarding “Plasma Concentration of Thrombopoietin in Dogs With Immune Thrombocytopenia”

Letter

Author: Wun, Matthew K.

100 Deals associated with BAH-1 (Genentech)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Thrombocytopenia	Discovery	United States	Genentech, Inc.	-

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data